Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

doi:10.1016/j.ejca.2022.10.003

Randomized Controlled Trial

. 2023 Jan:178:23-33.

doi: 10.1016/j.ejca.2022.10.003. Epub 2022 Oct 18.

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Sibylle Loibl¹, Delphine Loirat², Sara M Tolaney³, Kevin Punie⁴, Mafalda Oliveira⁵, Hope S Rugo⁶, Aditya Bardia⁷, Sara A Hurvitz⁸, Adam M Brufsky⁹, Kevin Kalinsky¹⁰, Javier Cortés¹¹, Joyce A O'Shaughnessy¹², Véronique Dieras¹³, Lisa A Carey¹⁴, Luca Gianni¹⁵, Mahdi Gharaibeh¹⁶, Luciana Preger¹⁷, See Phan¹⁸, Lawrence Chang¹⁶, Ling Shi¹⁹, Martine J Piccart²⁰

Affiliations

¹ Hämatologisch-Onkologische Gemeinschaftspraxis Am Bethanien-Krankenhaus, Frankfurt, Germany. Electronic address: sibylle.loibl@gbg.de.
² Medical Oncology Department and D3i, Institut Curie, Paris, France.
³ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
⁵ Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
⁶ Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
⁷ Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
⁸ Department of Medicine, Division of Hematology/Medical Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
⁹ Division of Hematology/Oncology, Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
¹⁰ Department of Medicine, Columbia University Irving Medical Center, New York, USA; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA.
¹¹ Oncology Department, International Breast Cancer Center (BCC), Pangaea Oncology, Quirónsalud, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain.
¹² Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
¹³ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
¹⁴ Medicine - Hematology/Oncology Division, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
¹⁵ Medical Oncology, Gianni Bonadonna Foundation, Milano, Italy.
¹⁶ Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁷ Department of Medical Affairs, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁸ Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁹ Evidence Synthesis, Modeling & Communication (EMC), Evidera PPD, Waltham, MA, USA.
²⁰ Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.

PMID: 36379186
PMCID: PMC11195534
DOI: 10.1016/j.ejca.2022.10.003

Randomized Controlled Trial

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Sibylle Loibl et al. Eur J Cancer. 2023 Jan.

. 2023 Jan:178:23-33.

doi: 10.1016/j.ejca.2022.10.003. Epub 2022 Oct 18.

Authors

Affiliations

¹ Hämatologisch-Onkologische Gemeinschaftspraxis Am Bethanien-Krankenhaus, Frankfurt, Germany. Electronic address: sibylle.loibl@gbg.de.
² Medical Oncology Department and D3i, Institut Curie, Paris, France.
³ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
⁵ Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
⁶ Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
⁷ Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
⁸ Department of Medicine, Division of Hematology/Medical Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
⁹ Division of Hematology/Oncology, Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
¹⁰ Department of Medicine, Columbia University Irving Medical Center, New York, USA; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA.
¹¹ Oncology Department, International Breast Cancer Center (BCC), Pangaea Oncology, Quirónsalud, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain.
¹² Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
¹³ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
¹⁴ Medicine - Hematology/Oncology Division, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
¹⁵ Medical Oncology, Gianni Bonadonna Foundation, Milano, Italy.
¹⁶ Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁷ Department of Medical Affairs, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁸ Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.
¹⁹ Evidence Synthesis, Modeling & Communication (EMC), Evidera PPD, Waltham, MA, USA.
²⁰ Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.

PMID: 36379186
PMCID: PMC11195534
DOI: 10.1016/j.ejca.2022.10.003

Abstract

Background: The antibody-drug conjugate sacituzumab govitecan (SG) prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, we investigated its effect on health-related quality of life (HRQoL).

Methods: This analysis was based on the open-label phase III ASCENT trial (NCT02574455). Adults with refractory/relapsed mTNBC who had received ≥2 prior systemic therapies (≥1 in the metastatic setting) were randomised 1:1 to SG or treatment of physician's choice (TPC; capecitabine, eribulin, vinorelbine, or gemcitabine). HRQoL was assessed on day 1 of each treatment cycle using the EORTC QLQ-C30. Score changes from baseline were analysed using linear mixed-effect models for repeated measures. Stratified Cox regressions evaluated time to first clinically meaningful change of HRQoL.

Results: The analysis population comprised 236 patients randomised to SG and 183 to TPC. For global health status (GHS)/QoL, physical functioning, fatigue, and pain, changes from baseline were superior for SG versus TPC. Compared with TPC, SG was inferior regarding changes from baseline for nausea/vomiting and diarrhoea but non-inferior for other QLQ-C30 domains. Median time to first clinically meaningful worsening was longer for SG than for TPC for physical functioning (22.1 versus 12.1 weeks, P < 0.001), role functioning (11.4 versus 7.1 weeks, P < 0.001), fatigue (7.7 versus 6.0 weeks, P < 0.05), and pain (21.6 versus 9.9 weeks, P < 0.001).

Conclusions: SG was generally associated with greater improvements and delayed worsening of HRQoL scores compared with TPC. This supports the favourable profile of SG as an mTNBC treatment.

Keywords: Antibody–drug conjugate; Clinical trial; EORTC QLQ-C30; Phase III; Quality of life; Sacituzumab govitecan; Triple-negative breast neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SL reports grants from Immunomedics during the conduct of the study. Outside the submitted work, SL has received grants and other from AbbVie, Amgen, AstraZeneca, and Celgene, grants, personal fees, and other from Daiichi Sankyo, grants and other from Novartis, Pfizer, and Roche, other from BMS, EirGenix, Lilly, Merck, MSD, Seagen, Prime/Medscape, PUMA, Samsung, and Pierre Fabre, grants from Teva and Vifor, and personal fees from Chugai. In addition, SL has a patent EP14153692.0 pending. DL has received consulting fees from MSD, Novartis, AstraZeneca, Roche, Immunomedics, and Pfizer and has obtained payment or honoraria from Amgen, MSD, Lilly, Novartis, BMS, and Roche. Support for attending meetings and/or travel were made to DL by Roche, MSD, AstraZeneca, and Novartis, and DL is on the Data Safety Monitoring Board or Advisory Board of MSD. SMT has obtained grants and personal fees from Immunomedics/Gilead during the conduct of the study. Outside of supported work, SMT has obtained grants and personal fees from AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Exelixis, Bristol Myers Squibb, Eisai, NanoString, Sanofi, Odonate, and Immunomedics/Gilead, personal fees from Puma, Celldex, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, AbbVie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi Sankyo, CytomX, Samsung Bioepis Inc., Certara, Mersana Therapeutics and grants from Cyclacel. KP has received honoraria for consultancy/advisory board functions and speaker fees from AstraZeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead Sciences, MSD, Novartis, Roche, and Seagen. KP's institution has received research grants from or had contracts with Sanofi and MSD; received consulting fees from AstraZeneca, Gilead Sciences, MSD, Novartis, Pfizer, and Roche; and received payment or honoraria from AstraZeneca, Eli Lilly, Gilead Sciences, MSD, Mundi Pharma, Novartis, Pfizer, and Roche. Support for attending meetings and/or travel was made to KP by AstraZeneca, Novartis, Pfizer, PharmaMar, and Roche. KP reports participation on a Data Safety Monitoring Board or Advisory Board of Eli Lilly, Gilead Sciences, MSD, Novartis, Pierre Fabre, Roche, Teva, and Vifor Pharma and is a board member of Belgian Society of Medical Oncology and Committee member of ESMO Young Oncologists and ESMO Resilience Task Force. KP has received equipment, materials, drugs, medical writing, gifts or other services from MSD and Gilead Sciences. MO has received grants from Immunomedics during the conduct of the study. Outside the submitted work, MO has obtained grants, personal fees, and non-financial support from Roche, grants and personal fees from Genentech, PUMA Biotechnology, Astra Zeneca, and Seattle Genetics, grants from Boehringer-Ingelheim, non-financial support from Pierre-Fabre, Eisai, GP Pharma, and Grünenthal, and grants, personal fees, and non-financial support from Novartis. HSR reports grants from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Seattle Genetics, Eisai, MacroGenics, Sermonix, Immunomedics, and AstraZeneca, non-financial support from Daiichi, Mylan, Pfizer, Merck, Novartis, AstraZeneca, and MacroGenics, personal fees from Mylan, Puma, and Samsung outside the submitted work. AB has obtained grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, and Immunomedics, grants and personal fees from Biotheranostics Inc., and personal fees from Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Sankyo Pharma/Astra Zeneca, Puma, Phillips, Eli Lilly, and Foundation Medicine outside the submitted work. SAH reports contracted research with Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, and Phoenix Molecular Designs, Ltd. and stock options with NK Max. AMB has obtained support for the present manuscript from Immunomedics/Gilead and consulting fees from Immunomedics/Gilead, Novartis, Genentech, Roche, Eisai, Merck and Athenex. KK received grants or contracts from Incyte, Novartis, Genentech, Lilly, Pfizer, Calithera, Immunomedics, Acetylon, Seattle Genetics, Amgen, Zeno, and CytomX, consulting fees from Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Genentech, Immunomedics, Merck, Seattle Genetics, Cyclacel, and OncoSec Medical, payment or honoraria from Lilly, and support for attending meetings and/or travel from Lilly, AstraZeneca, and Pfizer. KK is a member of the steering committee at Immunomedics, AstraZeneca, and Genentech. Other financial or non-financial interests of KK include spouse (employee) with Grail, Array, and Pfizer. JC holds consulting/advisor roles at Roche, Celgene, Celestial, AstraZeneca, Biothera Pharmaceuticals, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Kyowa Kirin and honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, and Daiichi Sankyo. JC receives research funding to the institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, and Queen Mary University of London. JC reports stock, patents, and intellectual property with MEDSIR and support for travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo. JAO has obtained consulting fees from AbbVie Inc., Agendia, Amgen, Aptitude Health, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, PUMA Biotechnology, Prime Oncology, Roche, Seattle Genetics, and Syndax Pharmaceuticals. VD has obtained honoraria from and holds consulting/advisory roles with Daiichi Sankyo, Gilead Sciences, MSD, Pierre Fabre Oncologie, Roche/Genentech, Novartis, Lilly, Pfizer, AstraZeneca, Eisai, AbbVie, and Seagen. VD reports participation in speakers' bureaus for and support for travel, accommodation, and expenses from Gilead, Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, and Seagen. LAC reports participation on a Data Safety Monitoring Board or Advisory Board of Sanofi Aventis, Novartis, Genentech/Roche, GSK, AstraZeneca/Daiichi Sanyo, and Aptitude Health. Other financial or non-financial interests of LAC includes spouse serving on the board of Falcon Therapeutics and spouse involvement in neural stem cell therapy patent. LG has received grants or contracts from Zymeworks and Revolution Medicines, consulting fees from Forty Seven (CD47), Genenta, METIS Precision Medicine, Novartis, Odonate Therapeutics, Revolution Medicines, Synaffix, Zymeworks, Menarini Ricerche, Amgen, and Biomedical Insights Inc., payment or honoraria from Roche, and support for attending meetings and/or travel from Pfizer. LG is a co-inventor of European patent Application N.12195182.6 and 12196177.5 titled PDL-1 expression in anti-HER2 therapy-Roche (issued) and reports participation on the advisory boards of ADC Therapeutics, AstraZeneca, Celgene, Eli Lilly, G1 Therapeutics, Genentech, Genomic Health, Merck Sharp & Dohme, Oncolytics Biotech, Odonate Therapeutics, Onkaido Therapeutics, Roche, Pfizer, Taiho Pharmaceutical, Hexal Sandoz, Seattle Genetics, Synthon, Zymeworks, Sanofi Aventis. MG has received stock or stock options at Gilead as an employee. LP has obtained support for attending meetings and/or travel and stock/stock options from Gilead due to employee status. SP and LC have obtained support for the present manuscript and stock/stock options from Gilead as employees. LS is an employee of Evidera, which received payment for the statistical analysis during the conduct of the study. MP has obtained research grant funding from AstraZeneca, Immunomedics, and Lilly, funding from Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon, and is a consultant at AstraZeneca and Roche-Genentech. MP is on the advisory boards of Debiopharm, Immunomedics, Immutep, Menarini, Odonate, Roche-Genentech, Seagen, Seattle Genetics, and has obtained support as an invited speaker at AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech. MP is a member of Board of Directors at Oncolytics.

Figures

**Fig. 1.. Least-square mean change from baseline for the primary-focused HRQoL domains.**
Data are from a mixed-effect model for repeated measures analysis. *P < 0.05 (SG versus TPC). C, cycle; D, day; HRQoL, health-related quality of life; LS, least-square; QoL, quality of life; SG, sacituzumab govitecan; TPC, treatment of physician’s choice.

**Fig. 2.. Time to first clinically meaningful worsening for the primary-focused HRQoL domains.**
[a] Estimated using a stratified Cox proportional hazards regression model with treatment arm (SG or TPC) and baseline score as covariates, and with number of prior systemic therapies for breast cancer, geographic region, and known brain metastases at study entry as stratification factors. Death was treated as an event. CI, confidence interval; HRQoL, health-related quality of life; QoL, quality of life; SG, sacituzumab govitecan; TPC, treatment of physician’s choice.

See this image and copyright information in PMC

Cited by

Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials.
Ding L, Yuan X, Wang Y, Shen Z, Wu P. Ding L, et al. BMJ Open. 2024 Jun 8;14(6):e077108. doi: 10.1136/bmjopen-2023-077108. BMJ Open. 2024. PMID: 38851227 Free PMC article.
Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.
Rossi V, Turati A, Rosato A, Carpanese D. Rossi V, et al. Front Immunol. 2024 Aug 15;15:1447280. doi: 10.3389/fimmu.2024.1447280. eCollection 2024. Front Immunol. 2024. PMID: 39211043 Free PMC article. Review.
Development and validation of a prognostic nomogram for breast cancer patients who underwent chemoradiotherapy and surgery: a retrospective cohort study based on the SEER database and two Chinese cohorts.
Wang H, Xia GF, Zhang ZR, Luo X, Zhu JY, Wang HK. Wang H, et al. Am J Cancer Res. 2023 Nov 15;13(11):5065-5081. eCollection 2023. Am J Cancer Res. 2023. PMID: 38058820 Free PMC article.
Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.
Wu Y, Hu S, Liu X, Chen Y, Luan J, Wang S. Wu Y, et al. Cost Eff Resour Alloc. 2024 Apr 24;22(1):32. doi: 10.1186/s12962-024-00539-y. Cost Eff Resour Alloc. 2024. PMID: 38659013 Free PMC article.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. Rugo HS, et al. Oncologist. 2024 Sep 6;29(9):768-779. doi: 10.1093/oncolo/oyae088. Oncologist. 2024. PMID: 38748596 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. O’Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021;12:164–82. - PMC - PubMed
1. Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res 2019;21:143. - PMC - PubMed
1. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J,et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast 2018;39:131–8. - PubMed
1. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018;9:28989–9006. - PMC - PubMed
1. Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920915980. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

P30 CA047904/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] O’Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021;12:164–82. - PMC - PubMed

[2] O’Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 2021;12:164–82. - PMC - PubMed

[3] Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res 2019;21:143. - PMC - PubMed

[4] Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res 2019;21:143. - PMC - PubMed

[5] Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J,et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast 2018;39:131–8. - PubMed

[6] Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J,et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast 2018;39:131–8. - PubMed

[7] Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018;9:28989–9006. - PMC - PubMed

[8] Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018;9:28989–9006. - PMC - PubMed

[9] Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920915980. - PMC - PubMed

[10] Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920915980. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Affiliations

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources